Luke_Wilbur

World now at the start of 2009 influenza pandemic Dr Margaret Chan Director-General of the World Health Organization Statement to the press by WHO Director-General Dr Margaret Chan 11 June 2009

Ocean Conservancy, Whale and Dolphin Conservation Society and Massachusetts Lobstermen Launch “Massachusetts lobster fishing: The right way" New program highlights steps taken by Massachusetts lobstermen to reduce impacts on whales when fishing; buying local lobster supports economy and future of endangered whales “Massachusetts lobster fishing: The right way” – a labeling and education program to distinguish lobster caught in Massachusetts using fishing practices that are safer for whales. Massachusetts Lobstermen’s Association, Massachusetts Division of Marine Fisheries, Ocean Conservancy and Whale and Dolphin Conservation Society are working with local restaurants, fish markets and seafood dealers to ensure that residents and visitors know to buy locally caught lobster. The signature green Massachusetts whale tail lobster claw band will signify lobster caught using safer fishing methods. These efforts ultimately support whale protection and the Massachusetts economy and lobster fishing heritage.

I hear that Von Brunn gave his computer away just before he committed that act.

I downloaded his book. Here is an excerpt... The purpose of this book is to present to WHITE YOUTH factual information conventionally suppressed or distorted by the mass media, and denied them by schools and universities — which are forced to promulgate the Marxist line or lose their government subsidies. Appearing throughout the text are quotes from world authorities whose credentials appear in the bibliography. Upon reading TOB SHEBBE GOYIM HAROG! (KILL THE BEST GENTILES!) you will understand that — despite loud protests of denial — an age old CONSPIRACY does exist to destroy Western Civilization. At this moment we are engaged in a deadly war with the HISTORIC ENEMY to determine whether or not our Nation will endure. We are losing that war because an Iron Curtain of censorship has descended over the landscape abrogating the First Amendment to the Constitution of the United States. Without Freedom of Speech our system of government cannot function. The hour is late. You and your family are in grave danger. We will present the FACTS then discuss what actions must be taken. Best wishes, James W. von Brunn Post Office Box 2821 Easton, Maryland 21601 8 June 1999 (Remember the U.S.S. Liberty.)

From the United States Holocaust Memorial Museum Mayor Adrian M. Fenty issued the following statement in response to the Holocaust Museum shooting incident that took the life of a security guard and critically wounded the gunman. The President and Secretary of the Interior Ken Salazar offer condolences. President Obama: Secretary Salazar: MPD, the FBI and the US Park Police are working together on this investigation. More information will be available tomorrow at an 8 am press conference. Detectives assigned to the Metropolitan Police Department’s Homicide Branch, with the assistance of members of the Federal Bureau of Investigation and the United States Park Police, are investigating a fatal shooting at the United States Holocaust Memorial Museum. Shortly before 1:00 on the afternoon of Wednesday, June 10, 2009, a lone gunman armed with a long gun opened fire on Special Police Officers (SPO’s) guarding the front entrance of the United States Holocaust Memorial Museum, located at 100 Raoul Wallenberg Place, SW (14th Street and Independence Avenue, SW). The gunman shot one SPO and was himself wounded by return gunfire from two other SPO’s. An off duty Metropolitan Police Department officer in the vicinity at the time the incident was dispatched, along with United States Park Police officers, immediately entered the museum and rendered first aid to the injured. The mortally wounded SPO and the as yet unidentified suspect were transported by DC Fire and Emergency Medical Services Department personnel to an area hospital where the SPO was pronounced dead and the suspect was admitted in critical condition. The SPO has been identified as 39-year-old Stephen Tyrone Johns of Temple Hills, Maryland.

General Motors begins its new chapter with the introduction of six all-new 2010 models that combine leading-edge design, technology, engineering excellence and quality, backed by the most comprehensive customer care package in the industry. Representing GM’s four core brands, new cars and crossovers launching for 2010 include the Buick LaCrosse luxury sedan; the Cadillac SRX crossover and Cadillac CTS SportWagon; the Chevrolet Camaro sports coupe and Chevrolet Equinox compact SUV; and the GMC Terrain compact SUV. In addition, Chevrolet’s iconic nameplate, Corvette, adds the Grand Sport, one of the most recognized names from Corvette’s illustrious racing heritage. “Our new 2010 model year vehicles are world-class, and they underscore our commitment to put our customers first in all that we do,” said Mark LaNeve, GM North America vice president, Vehicle Sales, Service and Marketing. “Add services that no other automaker offers – such as OnStar and expert Goodwrench service – and we provide the most complete ownership experience in the industry.” Technology leadership From advanced, fuel-saving engines and transmissions to features that warn drivers of blind spots and help them see around curves in nighttime driving, GM’s 2010 vehicles feature a wide range of technologies. New features by OnStar guide first responders to emergency scenes with exact latitude and longitude location data, and Injury Severity Prediction data that helps responders determine what level of care and transport is required. Direct injection engine technology delivers EPA-estimated highway fuel economy of 32 mpg in the Chevrolet Equinox and GMC Terrain – a 33 percent increase over the previous-generation models. GM engineers expect that fuel economy to lead the compact crossover market segment. Every new 2010 launch vehicle offers this fuel-saving engine technology. Four strong brands GM is using a court-supervised process to quickly launch a new, highly competitive company consisting of four strong, core brands – Buick, Cadillac, Chevrolet and GMC comprising 34 nameplates – a global footprint and industry-leading expertise and technology. Here’s a deeper look at GM’s new-for-2010 lineup: Buick LaCrosse: The all-new, 2010 Buick LaCrosse continues a Buick brand renaissance begun by the Enclave luxury crossover. The LaCrosse is a completely redesigned luxury sedan that offers a sculpted exterior and luxurious cabin; advanced, intelligent personal technologies and safety features; and a choice of two fuel-saving, direct injected V-6 engines. The 2010 LaCrosse is offered in three models: CX, CXL and CXS. A choice of front-wheel drive and all-wheel drive is available. Other 2010 Buick models: Enclave and Lucerne. Cadillac GM’s luxury brand launches two vehicles for 2010 – the SRX crossover and the CTS Sport Wagon – that add new dimensions to the luxury marketplace, while featuring Cadillac’s signatures of dramatic design and technology. SRX: The completely new SRX crossover enters one of the luxury market’s largest and strongest segments, offering a more dynamic alternative. With a dramatic design inside and out, the new SRX brings more emotion to the previously conservative luxury crossover category, which now accounts for nearly a quarter of the total luxury market in the United States. A new, 3.0L direct injected V-6 engine is standard, and a new, 2.8L turbocharged V-6 is optional. Both employ advanced technology that helps produce strong performance that is typical of larger-displacement engines, but with greater fuel economy and lower emissions. An advanced all-wheel-drive system created for the new SRX transfers torque front-to-back and also laterally on the rear axle for superior traction and control on slippery surfaces, and responsive handling on dry pavement. CTS Sport Wagon: The CTS Sport Wagon is also new for 2010, expanding the CTS lineup with a cutting-edge design and much more space and utility than its sedan counterpart. The CTS Sport Wagon is Cadillac’s first-ever North American wagon. It is a progressive take on the classic wagon body style that delivers significant functionality and fuel efficiency, including up to an estimated 28 mpg highway. Essentially the same size as the acclaimed CTS sport sedan on the outside, it nearly doubles cargo carrying capacity, with 25 cubic feet (720 liters) of space behind the rear seats and 53.4 cubic feet (1,523 liters) with the rear seat folded. Other 2010 Cadillac models: CTS and CTS-V, DTS, STS, Escalade, Escalade ESV and Escalade EXT. Chevrolet Camaro: The new Chevrolet Camaro returns after a seven-year hiatus, and is better than ever. The Camaro’s combination of efficient performance blends with dramatic, heritage-inspired design and great refinement in a distinctive package that exemplifies Chevrolet’s commitment to great looking, fuel-efficient cars for all customers. Camaro’s advanced 3.6L, direct injected V-6 delivers performance and efficiency, with 304 horsepower (227 kW) and EPA-rated 29 mpg in highway driving in LT and LS models. For those lured by the intoxication of small-block V-8 power, the performance-oriented Camaro SS offers a pair of 6.2L V-8s – including one with Active Fuel Management that helps improve fuel economy by shutting down four cylinders during certain light-load driving conditions. Equinox: New for 2010, Equinox blends distinctive design and outstanding roominess with class-leading efficiency. Chevrolet expects nearly two-thirds of customers will choose the efficient 2.4L engine – standard on all models – that delivers an EPA-estimated 32 mpg highway. The new Equinox draws its exterior design inspiration from the Chevrolet Malibu sedan and Traverse crossover; and like those vehicles, the new Equinox complements its styling with attention to detail and unexpected features. It is available in LS, LT and LTZ trim, with available all-wheeldrive. Both the new, 2.4L engine and an available 3.0L V-6 feature fuel-saving direct injection and variable valve timing technology, as well as fuel-saving six-speed transmissions. Equinox retains its popular MultiFlex rear seat design, allowing the seat to be moved fore or aft nearly eight inches (203 mm), for the best rear legroom in its class. With the 60/40-split-back rear seat moved all the way forward, the cargo area offers 31.4 cubic feet (889 liters) of storage. Corvette Grand Sport: Grand Sport is one of the most storied monikers in Corvette’s illustrious racing heritage. For 2010, it once again becomes part of the Corvette’s lineup, available in coupe and convertible models. Replacing the previous Z51 package, the new Grand Sport brings a greater degree of handling performance, with wider wheels and tires; wider fenders; distinctive exterior styling cues; revised shock, stabilizer bar and spring specifications; and specific gearing. Grand Sport coupe models equipped with the manual transmission are uniquely outfitted for race track competition, too, with a dry-sump oiling system, differential cooler and a rear-mounted battery. Other Chevrolet models: Aveo, Cobalt, Malibu, Impala, Corvette, Corvette Z06, Corvette ZR1, Traverse, Tahoe, Suburban, Silverado, Express. GMC Terrain: The all-new GMC Terrain crossover SUV offers outstanding fuel economy along with the capability, engineering excellence and refinement that have defined GMC for more than a century. It joins a diverse lineup filled with technologically advanced hybrids, efficient utilities and trucks designed to tackle any worksite task. A new, 2.4L four-cylinder engine that features direct injection delivers the Terrain’s expected best-in-segment, EPA-rated highway fuel economy of 32 mpg (FWD models). Maximum fuel economy is achieved in part with an “ECO” mode that is activated via a console-mounted button. When engaged, it lowers the torque converter lockup speed to help save fuel on models equipped with the 2.4L engine. A 3.0L DOHC direct injected V-6 engine is also available. Both engines are mated to efficiency-enhancing, six-speed automatic transmissions, and offer a refined, confident driving experience. The 2010 Terrain is offered in SLE and SLT trim levels, featuring standard and available content such as a rear-vision camera, programmable power rear liftgate, Bluetooth connectivity, MultiFlex sliding rear seat, remote vehicle start and OnStar. Other GMC models: Acadia, Yukon, Yukon XL, Sierra. A greener GM Besides fuel-saving technologies such as direct injected engines and six-speed transmissions, GM is using other advanced technologies to save fuel and reduce carbon emissions. For 2010, GM offers seven models with exclusive, fuel-saving 2-Mode hybrid technology, including the Cadillac Escalade Hybrid and Escalade Platinum Hybrid; the Chevrolet Tahoe Hybrid SUV and Silverado Hybrid pickup; and the GMC Yukon Hybrid, Yukon Denali Hybrid and Sierra Hybrid pickup. GM also offers 13 models with E85 FlexFuel capability, joining the more than 2 million GM FlexFuel vehicles already on the road. E85 is a renewable, domestically produced biofuel that helps reduce petroleum consumption. GM also is marching aggressively toward the late-2010 launch of the Chevrolet Volt extended-range electric vehicle, powered by GM’s exclusive Voltec propulsion technology. For trips of up to 40 miles, the Volt is powered by electricity from the grid and stored in its lithium-ion battery pack. Beyond 40 miles, a small engine-generator creates additional electricity to extend the range of the Volt several hundred additional miles until the driver can plug-in to recharge the battery. GM is ramping up its in-house advanced battery development, which is at the heart of the Voltec system.

APC stated that they will honor the computer repair as long as I have a receipt. I am contacting Phone: 304-372-8186 Toll Free: (866)293-1667 Emails: support@computersandwireless101.com sales@computersandwireless101.com webmaster@computersandwireless101.com

1-877-800-4272 I spoke with Jonna of the APC Claim Department located in the Philippines. Two for surge only. We will be receiving the same unit with the claim. Claim No. 1-1013748340 The claims department is actually done West Kingston, Rhode Island.

I spoke Soheib at Hughes Tech Support. We are a business customer and not be able to communicate with our customers. Ref# 18535284 Tel 866-347-3292 Soheib transferred to Angie of small business support. Hughes stated that transmitter is not communicating. Soheib stated that we have somebody will actually bring the modem to our farm before Friday. What a great service : )

Your question has been received. You should expect a response from us within the next business day. Question Reference #090610-000333 --------------------------------------------------------------- Summary: APC Battery Backup did not protect from Power Surge Product Level 1: Back-UPS Battery Systems Category Level 1: Technical Assistance Date Created: 06/09/2009 03:43 PM Last Updated: 06/09/2009 03:43 PM Status: Unresolved Model Number: BR800BLK Serial: 5B0727U09748 Management Software: Version: Operating System: Windows XP Discussion Thread --------------------------------------------------------------- Customer (Luke Wilbur) - 06/09/2009 03:43 PM APC did not protect my computer and printer from a power surge. My modem, computer, and printer are fried. [---001:000909:14824---]

Left online ticket Reference # 090610-000333 Product Back-UPS Battery Systems Date Created 06/09/2009 03:43 PM Last Updated 06/09/2009 03:43 PM Status Unresolved Model Number BR800BLK Serial 5B0727U09748 Operating System Windows XP http://nam-en.apc.com/cgi-bin/nam_en.cfg/p...p_pv=&p_cv=

An electrical surge went through my APC Battery surge protector and fried my computer. Model No. BR800BLK Serial No. 5B0727U09748 Computer - Fried Sony VIAO Printer - Fried Lexmark X4270 Hughes Satellite Modem - Fried Model No - HN7000S PSN No. - HJN27G285038358748

Joe. Do not worry. We are in this together. Eli Lilly Plea and Settlement Eli Lilly and Company (Eli Lilly) and the government (the Office of the United States Attorney for the Eastern District of Pennsylvania and the Office of Consumer Litigation of the Department of Justice) entered into an agreement whereby Eli Lilly agrees to plead guilty to the introduction into interstate commerce of quantities of its drug, Zyprexa, that were misbranded in violation of 21 U.S.C. §§ 331(a), 333(a)(1) and 352(f)(1). Specifically, Eli Lilly will plead guilty to promoting Zyprexa in elderly populations as treatment for dementia, including Alzheimer's dementia, between September 1999 and March 31, 2001. The entry of plea and sentencing hearing in this matter will be held before the Honorable Robert F. Kelly on Friday, January 30, 2009, at 10:00 a.m. in Courtroom 11B, 11th floor of the United States District Court, United States Courthouse, 601 Market Street, Philadelphia, Pennsylvania. The case has been assigned the criminal docket number 09-020. All government filings, both criminal and civil, are available for your convenience on the following links: Information Guilty Plea Agreement Government's Memorandum For Entry Of Plea and Sentencing Corporate Integrity Agreement Settlement Agreement Government's Supplemental Motion in Anticipation of Sentencing and Judgment and Order of Forfeiture To see the statement issued by Acting United States Attorney Laurie Magid, click here. To see a press release issued by the United States Attorney's Office for the Eastern District of Pennsylvania, click here. To see a press release issued by the United States Attorney's Office for the Eastern District of Pennsylvania, click here.

PHARMACEUTICAL COMPANY ELI LILLY TO PAY RECORD $1.415 BILLION FOR OFF-LABEL DRUG MARKETING Criminal Penalty is Largest Individual Corporate Criminal Fine PHILADELPHIA – United States Attorney General Michael B. Mukasey and Acting United States Attorney Laurie Magid today announced the filing of a criminal information against, and a civil settlement with, pharmaceutical company Eli Lilly and Company, headquartered in Indianapolis, Indiana, for the off-label marketing of the anti-psychotic drug Zyprexa. The monetary settlement, totaling $1.415 billion, is the largest amount paid by a single defendant in the history of the United States Department of Justice (“DOJ”). Joining Mukasey and Magid in today’s announcement were Assistant Attorney General Gregory Katsas, who is in charge of DOJ’s Civil Division; Director of DOJ’s Office of Consumer Litigation, Eugene Thirolf; Special Agent-in-Charge of the Defense Criminal Investigative Service Ed Bradley; Special Agent-in-Charge of the Food and Drug Administration, Office of Criminal Investigations Kim Rice; and Special Agent-in-Charge Patrick Doyle of the Office of Inspector General of the Department of Health and Human Services. The Criminal Charge The information charges Eli Lilly with the misdemeanor of introducing misbranded drugs into interstate commerce between September 1999 and November 2003. The Food and Drug Administration (“FDA”) had approved Zyprexa for use by adults for treatment of schizophrenia and certain types of bipolar disorder. Eli Lilly has admitted that it illegally marketed Zyprexa for uses never approved by the FDA. Among other things, the government alleges that these uses included treatment of elderly patients for such things as sleep disorders and dementia. According to the information, Eli Lilly targeted its illegal marketing of Zyprexa to two types of doctors: those who treat the elderly in nursing homes and assisted living facilities, and primary care physicians. In September 1999, Eli Lilly began encouraging doctors to prescribe the drug for the treatment of dementia, Alzheimer’s, agitation, aggression, hostility, depression, and generalized sleep disorder. Zyprexa was not approved for use for any of these disorders, which, unlike schizophrenia, are prevalent in the elderly population. Nevertheless, Eli Lilly’s long-term care sales force promoted the use of Zyprexa in elderly populations for these symptoms. Because one of Zyprexa’s side effects is sedation, Eli Lilly directed its long-term care sales force to tell doctors that Zyprexa would help patients with sleep problems, behavioral issues, and dementia. They claimed this side effect was a therapeutic benefit, not an adverse event, with the sales slogan “5 at 5,” that five milligrams of Zyprexa at 5 p.m. would help their patients sleep. Then in 2000, Eli Lilly expanded its illegal marketing to primary care physicians with its primary care sales force in the “Viva Zyprexa” campaign, adding even more sales representatives. The goal of the campaign was to make Zyprexa an “everyday agent in primary care” even though the company recognized that schizophrenia and bipolar disorder were not viewed as conditions typically treated by primary care physicians. Lilly instructed the sales force to recommend Zyprexa for all adult patients with behavioral symptoms like agitation, aggression, hostility, mood and sleep disturbances, and depression. The information alleges that Eli Lilly’s illegal off-label marketing campaign raised safety issues and posed potential risk to patients. Eli Lilly knew that significant weight gain and obesity were adverse side effects of Zyprexa and that weight gain and obesity were factors in causing hyperglycemia and diabetes. Yet despite written caution from the FDA, Eli Lilly continued to promote these adverse events as therapeutic benefits of Zyprexa use, particularly in the elderly. Eli Lilly’s management created marketing materials promoting Zyprexa for off-label uses, trained its sales force to disregard the law, and directed its sales personnel to promote Zyprexa for off-label uses. Anticipating the possibility of resistance from primary care physicians to prescribing Zyprexa, defendant Eli Lilly specifically trained its sales representatives on how to respond to doctors’ concerns about off-label uses of Zyprexa, and how to continue to promote Zyprexa for off-label conditions. Eli Lilly retained medical professionals to speak to doctors during peer-to-peer sessions about off-label uses of Zyprexa. When promoting Zyprexa to health care providers, Lilly emphasized that the weight gain side effect of the drug was a therapeutic benefit for patients who had trouble maintaining their weight. "When pharmaceutical companies interfere with the FDA’s mission to insure that drugs are safe and effective, they undermine the doctor-patient relationship and put the health and safety of patients at risk,” said Magid. “People have a legal right to know that pharmaceutical companies are marketing their drugs only for uses approved by the FDA and that their doctors’ judgment has not been affected by misinformation from a pharmaceutical company trying to boost revenues.” In a plea agreement with the United States, Eli Lilly will pay a total of $615 million, including a $515 million fine and $100 million in forfeiture. “Off-label promotion of pharmaceutical drugs is a serious crime because it undermines the FDA’s role in protecting the American public by determining a drug is safe and effective for a particular use before it is marketed,” said Gregory G. Katsas, Assistant Attorney General for the Civil Division. “This settlement demonstrates the Department’s ongoing diligence in prosecuting cases involving violations of the Food, Drug, and Cosmetic Act, and recovery of taxpayer dollars used to pay for drugs sold as a result of off-label marketing campaigns.” The Civil Settlement In a separate civil settlement agreement, Eli Lilly agreed to pay the United States approximately $438,171,543.58 to settle allegations that it caused invalid claims for payment for Zyprexa to be submitted to various government programs such as Medicaid, TRICARE, and the Federal Employees Health Benefits Program and caused purchases of Zyprexa by the Department of Veterans Affairs, the Bureau of Prisons, the Department of Defense, the Defense Logistics Agency, the Department of Labor, and Public Health Service entities for unapproved off-label uses. Also, Eli Lilly agreed to pay various state Medicaid programs more than $361,828,456.42 to settle similar claims. “Today’s announcement of the filing of a criminal charge and the unprecedented terms of this settlement demonstrate the government’s increasing efforts aimed at pharmaceutical companies that choose to put profits ahead of the public’s health,” said Special Agent-in-Charge Kim Rice, of FDA’s Office of Criminal Investigations. “The FDA will continue to devote resources to criminal investigations targeting pharmaceutical companies that disregard the safeguards of the drug approval process and recklessly promote drugs for uses for which they have not been proven to be safe and effective.” “The illegal scheme used by Eli Lilly significantly impacted the integrity of the Department of Defense’s healthcare system,” said Special Agent-in-Charge of the Defense Criminal Investigative Service Ed Bradley. “This illegal activity increases patients’ costs, threatens their safety and negatively affects the delivery of health care services to the more than nine million military members, retirees and their families who rely on this system. Today’s charges and settlement demonstrate the ongoing commitment of the Defense Criminal Investigative Service and its partners in law enforcement to investigate and prosecute those that abuse the government’s healthcare programs at the expense of the taxpayers and patients.” “Today’s disclosures should send a clear message to those doing business with the Government that they will be held accountable for their decisions and actions that have an adverse impact on health care programs, such as Medicare and Medicaid,” said Special Agent-in- Charge Patrick Doyle, HHS, Office of Inspector General, Office of Investigations. “Our office is committed to pursuing those companies and individuals who choose to put profits ahead of the law.” The civil settlement also resolves four whistle-blower lawsuits filed in federal court here: United States of America ex rel. Robert Rudolph v. Eli Lilly and Company, Civil Action No. 03- 943; United States of America ex rel. Joseph Faltaous v. Eli Lilly and Company, Civil Action No. 05-1471; United States of America ex rel. Steven Woodward v. Eli Lilly and Company, Civil Action No. 06-5526; and United States of America ex rel. Jaydeen Vincente v. Eli Lilly and Company, Civil Action No. 07-1791. Those cases were filed by former sales representatives who identified Eli Lilly’s off-label marketing practices. To encourage individuals to come forward and identify companies and individuals that defraud the government, federal law permits whistle blowers to share in the recovery for such fraud. In this case, the whistle blowers will share in 18%, or $78,870,877, of the federal share of the (civil) settlement. The HHS Office of Inspector General and Eli Lilly entered into an agreement that requires Eli Lilly to cease off-label marketing and to put certain programs in place to prevent the illegal conduct from recurring. This agreement, called a Corporate Integrity Agreement, requires Eli Lilly to send doctors letters advising them of this resolution and give them a way to report questionable conduct of sales representatives, list payments to doctors on its website, and assure that its board of directors and top management regularly certify that the company obeys the law and has an effective compliance program. This case was investigated by the Defense Criminal Investigative Service, the FDA’s Office of Criminal Investigations, and the Department of Health and Human Services Office of the Inspector General. The case is being prosecuted by Assistant United States Attorneys Catherine L. Votaw, Marilyn May, Joseph Trautwein, and Denise S. Wolf, and DOJ Office of Consumer Litigation Trial Attorneys Jeffrey Steger and Ross Goldstein. Assistance was provided by representatives of FDA’s Office of Chief Counsel and the National Association of Medicaid Fraud Control Units. The Corporate Integrity Agreement was negotiated by the Office of Inspector General of the Department of Health and Human Services. Eli Lilly’s guilty plea and sentence are not final until accepted by the United States District Court. UNITED STATES ATTORNEY'S OFFICE Contact: PATTY HARTMAN EASTERN DISTRICT, PENNSYLVANIA Media Contact Suite 1250, 615 Chestnut Street 215-861-8525 Philadelphia, PA 19106 COPIES OF NEWS MEMOS AND RELATED DOCUMENTS CAN ALSO BE FOUND AT http://www.usdoj.gov/usao/pae

Just received a call this afternoon from Brown & Crouppen, Attorneys at Law. They told me that they are no longer accepting claim applications. The attorney advised Joe to contact the District of Columbia Bar and see who else is pursuing the case.

Joe and I went to CVS pharmacy at Wildwood Shopping Center in Bethesda, Maryland this last Friday. CVS told Joe that his medicaid was not allowing Joe to get Nexium. Nexium is used in the treatment of Gastroesophageal Reflux Disease (GERD). Healing of Erosive Esophagitis NEXIUM® is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. Joe's excessive vomiting is a common symptoms of Reflux. His doctor prescribed Nexium to combat the Gastritis found in the lining of his stomach. Joes' prolonged use of Ziprixa has had an effect on his body.

What Tagged and other social networking sites are doing is ethically wrong in my opinion. They harvest emails and spam their friends. Of course these social networking sites do ask for permission. There is no laws broken at this point of time. Cyberspace discourse is a new frontier to our collective minds.

It is a hard pill to swallow to assume the Rothschild family makes all the decisions in the world. It is even more difficult to believe that they are Illuminati occultists that want to profit by seeding wars to gain power in a New World Order with its capital in Israel. I did like reading the history. I wonder how much of it is just a conspiracy fantasy.

It is an amazing time to be living.

It is hard for those of us that live in a democratic social atmosphere to imagine a place where there is little religious freedom.

Michelle Hawkins was not in the office. Her voice mail stated to contact her supervisor, Alice M. Anderson, at 202-730-1745. Left message with Alice Anderson. Kim Wilson stated that the Eckington Service Center did receive Joe's fax and will update his case.

Here is an update on Joe's status. We just faxed Joe's "Discharge from Maryland Medical Assistance" to Kim Wilson of the Eckington Service Center at 202.724-4989. Joe is going to call Kim Wilson to see if she has in fact received the fax. In addition, Joe has to fill out another form for District of Columbia department of Disability Services. I am going to contact Denise Gomez, M.S. Program Specialist II Montgomery County Dept. of Health & Human Services Resource Coordination 11 N. Washington St., Ste. 450 Rockville, MD 20850 Phone. (240) 777-4524, Fax. (240) 777-4625 Denise worked with Joe over the years and really helped him. We are very grateful for her services. I am going to have her contact Michelle Hawkins Community Outreach Specialist Intake and Eligibility Unit 202.730-1813 Michelle stated that I would have to prove that Joe has a mental disability. Hopefully Denise can help us with that. http://dds.dc.gov http://dds.dc.gov/dds/site/default.asp

This is completely absurd. Maryland and the District benefits departments do not want to communicate with each other. Each one offers their general telephone numbers to each other. What is even more absurd is they do not have the staff to answer the calls. The only way you can actually get something done is wait in line for five hours to get a five minute consultation of what needs to be done next. Now the Eckington service center is stating that Joe is over qualified since he is getting survivor benefits from the death of his mother and father. He gets a check for $1,100.00 from Social Security. That is it. Mrs White said he Joe is going to have to spend down to get his benefits. This means will be only allowed to have $600.00 a month to use for his food and shelter.

Francesca Dennis was completely helpful restoring Joe's Montgomery County benefits. told me that all of Joe's health benefits are up. Francesca stated that Joe will receive a bill from Conexis in the mail. We are going to 101 Monroe Street, 7th Floor Rockville, Maryland. Park in the Jury lot. Joe found out that his bills were formerly paid by his mother. His mother's family was supposed to pay the bills. There was no payment to Conexis since March 2009. His current bill with Conexis is close to $1000.00. Conexis stopped coverage. Joe also found out that the State of Maryland terminated his Medicaid coverage before he had transferred over to the District's Medicaid Network. Therefore Joe currently had no primary or secondary coverage. Francesca stated that Joe's prescription coverage should have been reinstated. Joe now has to pay all money up front and wait to get reimbursed. Francesca stated that he will have to decide whether or not we want to continue coverage. 240-777-5120

There is a loophole that Congress needs to fix. If you deposit checks you received in the mail to the bank. The Company is then authorized to withdraw money from your bank account.